Royalty Pharma to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
28 nov. 2022 16h26 HE
|
Royalty Pharma plc
NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Virtual...
Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones
09 nov. 2022 08h49 HE
|
Royalty Pharma plc
Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease Arrowhead retains rights to $400 million in development, regulatory and sales milestone payments...
Royalty Pharma Reports Third Quarter 2022 Results
08 nov. 2022 07h00 HE
|
Royalty Pharma plc
Net cash provided by operating activities (GAAP) of $539 million and Adjusted Cash Receipts(1) (non-GAAP) of $597 million Announced transactions of up to $3.0 billion year-to-date, including...
Royalty Pharma to Announce Third Quarter 2022 Financial Results on November 8, 2022
18 oct. 2022 08h30 HE
|
Royalty Pharma plc
NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022 before the...
Royalty Pharma Declares Fourth Quarter 2022 Dividend
17 oct. 2022 08h30 HE
|
Royalty Pharma plc
NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2022 of $0.19 per Class A...
Royalty Pharma Announces Expansion of Leadership Team
12 oct. 2022 16h15 HE
|
Royalty Pharma plc
Art McGivern joins Royalty Pharma as EVP, Investments & General CounselGeorge Lloyd promoted to EVP, Investments & Chief Legal Officer NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Royalty...
Royalty Pharma Announces R&D Funding Collaboration With Merck
12 oct. 2022 07h00 HE
|
Royalty Pharma plc
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada, to...
Royalty Pharma to Present at Upcoming Investor Conferences
06 sept. 2022 16h15 HE
|
Royalty Pharma plc
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: ...
Royalty Pharma Reports Second Quarter 2022 Results
04 août 2022 07h00 HE
|
Royalty Pharma plc
Strong growth in net cash provided by operating activities and Adjusted Cash Receipts(1)Announced transactions of up to $2.5 billion year-to-date, including $1.7 billion in upfront paymentsIncreased...
Royalty Pharma to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
08 juin 2022 08h30 HE
|
Royalty Pharma plc
NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 43rd Annual Global Healthcare Conference on June...